Patents by Inventor Amala Kompella

Amala Kompella has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240199637
    Abstract: The present invention describes an improved second generation process for the synthesis of NRC-1111 (1,5-[2-[[4-(methylsulfonyl)-1-piperazinyl]methyl]-7-(4-morpholinyl)thieno[2,3-c] pyridine-5-yl]-2-pyrimidinamine) dimethane sulfonate and NRC-1109 (II, 5-[3-methyl-2-[(4-methylsulfonylpiperazin-1-yl)methyl]-7-morpholino-thieno[2,3-c]pyridin-5-yl]pyrimidin-2-amine) dimethane sulfonate. This process is cost effective, high yielding and industrially feasible process for the synthesis of compounds of formulae I and II with high purity. Formula (I) Formula (I): R?H for NRC-1111 and Formula (II): R?CH3 for NRC-1109 NRC-1111 and NRC-1109 are potential anti-cancer agents.
    Type: Application
    Filed: April 15, 2022
    Publication date: June 20, 2024
    Inventors: Amala KOMPELLA, Kameswara Rao VAGICHERLA, Tirumala Reddy LANKI REDDY, Narmada PESARU, Pulla Reddy MUDDASANI, Venkaiah Chowdary NANNAPANENI
  • Patent number: 10870650
    Abstract: The present invention relates to a process for the preparation of stable and 5 pure amorphous form of Idelalisib. Further, the present process is simple, more economical, cost effective and efficient method of manufacturing that is suitable for industrial scale-up having a high degree of chromatographic purity.
    Type: Grant
    Filed: April 11, 2018
    Date of Patent: December 22, 2020
    Assignee: NATCO PHARMA LIMITED
    Inventors: Amala Kompella, Sreenivas Rachakonda, Venugopala Krishna Gampa, Subhash Kusumba, Durga Prasad Konakanchi, Pulla Reddy Muddasani, Venkaiah Chowdary Nannapaneni
  • Publication number: 20200095249
    Abstract: The present invention relates to a process for the preparation of stable and 5 pure amorphous form of Idelalisib. Further, the present process is simple, more economical, cost effective and efficient method of manufacturing that is suitable for industrial scale-up having a high degree of chromatographic purity.
    Type: Application
    Filed: April 11, 2018
    Publication date: March 26, 2020
    Inventors: Amala KOMPELLA, Sreenivas RACHAKONDA, Venugopala Krishna GAMPA, Subhash KUSUMBA, Durga Prasad KONAKANCHI, Pulla Reddy MUDDASANI, Venkaiah Chowdary NANNAPANENI
  • Patent number: 10047088
    Abstract: The present invention relates to novel antiproliferative 1H-1, 8-naphthyridin-2-ones of the general formula (I) or pharmaceutically acceptable salts thereof: In which the variable groups are as defined herein, and their preparation and use in therapeutic treatment of disorders related to inhibition of tyrosine kinases in warm blooded animals. The compounds can overcome imatinib induced drug resistance.
    Type: Grant
    Filed: August 18, 2017
    Date of Patent: August 14, 2018
    Assignee: NATCO PHARMA LIMITED
    Inventors: Amala Kompella, Venugopala Krishna Gampa, Srinivasulu Ganganamoni, Balakrishna Reddy Sirigireddy, Kali Satya Bhujanga Rao Adibhatla, Venkaiah Chowdary Nannapaneni
  • Publication number: 20170349588
    Abstract: The present invention relates to novel antiproliferative 1H-1, 8-naphthyridin-2-ones of the general formula (I) or pharmaceutically acceptable salts thereof: In which the variable groups are as defined herein, and their preparation and use in therapeutic treatment of disorders related to inhibition of tyrosine kinases in warm blooded animals. The compounds can overcome imatinib induced drug resistance.
    Type: Application
    Filed: August 18, 2017
    Publication date: December 7, 2017
    Inventors: Amala KOMPELLA, Venugopala Krishna GAMPA, Srinivasulu GANGANAMONI, Balakrishna Reddy SIRIGIREDDY, Kali Satya Bhujanga Rao ADIBHATLA, Venkaiah Chowdary NANNAPANENI
  • Patent number: 9765072
    Abstract: The present invention relates to novel antiproliferative 1H-1, 8-naphthyridin-2-ones of the general formula (I) or pharmaceutically acceptable salts thereof: In which the variable groups are as defined herein, and their preparation and use in therapeutic treatment of disorders related to inhibition of tyrosine kinases in warm blooded animals. The compounds can overcome imatinib induced drug resistance.
    Type: Grant
    Filed: December 15, 2014
    Date of Patent: September 19, 2017
    Assignee: NATCO PHARMA LIMITED
    Inventors: Amala Kompella, Venugopala Krishna Gampa, Srinivasulu Ganganamoni, Balakrishna Reddy Sirigireddy, Kali Satya Bhujanga Rao Adibhatla, Venkaiah Chowdary Nannapaneni
  • Publication number: 20170114057
    Abstract: The present invention relates to novel antiproliferative 1H-1,8-naphthyridin-2-ones of the general formula (I) or pharmaceutically acceptable salts thereof: In which the variable groups are as defined herein, and their preparation and use in therapeutic treatment of disorders related to inhibition of tyrosine kinases in warm blooded animals. The compounds can overcome imatinib induced drug resistance.
    Type: Application
    Filed: December 15, 2014
    Publication date: April 27, 2017
    Inventors: Amala KOMPELLA, Venugopala Krishna GAMPA, Srinivasulu GANGANAMONI, Balakrishna Reddy SIRIGIREDDY, Kali Satya Bhujanga Rao ADIBHATLA, Venkaiah Chowdary NANNAPANENI
  • Patent number: 9440959
    Abstract: The present invention relates a process for the preparation of a compound of formula (I): or a pharmaceutically acceptable salt thereof, which process comprises converting a compound of formula (IV): or a pharmaceutically acceptable salt thereof, into the compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: March 17, 2015
    Date of Patent: September 13, 2016
    Assignee: Natco Pharma Limited
    Inventors: Amala Kompella, Adibhatla Kali Satya Bhujanga Rao, Sreenivas Rachakonda, Venugopala Krishna Gampa, Venkaiah Chowdary Nannapaneni
  • Publication number: 20150183762
    Abstract: The present invention relates a process for the preparation of a compound of formula (I): or a pharmaceutically acceptable salt thereof, which process comprises converting a compound of formula (IV): or a pharmaceutically acceptable salt thereof, into the compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: March 17, 2015
    Publication date: July 2, 2015
    Inventors: Amala Kompella, Adibhatla Kali Satya Bhujanga Rao, Sreenivas Rachakonda, Venugopala Krishna Gampa, Venkaiah Chowdary Nannapaneni
  • Patent number: 9061028
    Abstract: The present invention relates a process for the preparation of a compound of formula (I): or a pharmaceutically acceptable salt thereof, which process comprises converting a compound of formula (IV): or a pharmaceutically acceptable salt thereof, into the compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 15, 2012
    Date of Patent: June 23, 2015
    Assignee: Natco Pharma Limited
    Inventors: Amala Kompella, Adibhatla Kali Satya Bhujanga Rao, Sreenivas Rachakonda, Venugopala Krishna Gampa, Venkaiah Chowdary Nannapaneni
  • Publication number: 20130210847
    Abstract: The present invention relates a process for the preparation of a compound of formula (I): or a pharmaceutically acceptable salt thereof, which process comprises converting a compound of formula (IV): or a pharmaceutically acceptable salt thereof, into the compound of formula (I) or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: February 15, 2012
    Publication date: August 15, 2013
    Applicant: Natco Pharma Limited
    Inventors: Amala Kompella, Adibhatla Kali Satya Bhujanga Rao, Sreenivas Rachakonda, Venugopala Krishna Gampa, Venkaiah Chowdary Nannapaneni
  • Publication number: 20130184490
    Abstract: Disclosed is a process for the preparation of S-2-Hydroxy-3-methoxy-3,3-diphenylpropionic acid (I) the key intermediate for the preparation of Ambrisentan [(+)-2(S)-(4,6-Dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid]. Ambrisentan of the formula (IA) is approved under the trademark “Letairis ®” by the US Food and Drug Administration for the treatment of Pulmonary artery hypertension (PAH).
    Type: Application
    Filed: August 4, 2010
    Publication date: July 18, 2013
    Applicant: NATCO PHARMA LIMITED
    Inventors: Amala Kompella, Kali Satya Bhujanga Rao Adibhatla, Veera Swamy Balina, Srinivasu Kasa, Venkaiah Chowdary Nannapaneni
  • Publication number: 20130172571
    Abstract: Disclosed is a process for the preparation of Ethyl 4-methyl-2-(4-(2-methylpropyloxy)-3-cyanophenyl)-5-thiazolecarboxylate (I) the key intermediate for the preparation of [2-[3-cyano-4-(2-Methyl-propoxy)phenyl]-4-methyl-5-thiazole carboxylic acid (Febuxostat, I(A)) is approved under the trademark Uloric® by the US Food and Drug Administration for the treatment of hyperuricemia and gouty arthritis.
    Type: Application
    Filed: September 8, 2010
    Publication date: July 4, 2013
    Applicant: NATCO PHARMA LIMITED
    Inventors: Amala Kompella, Venue Gopala Krishna Gampa, Kali Satya Bhujanga Rao Adibhatla, Venkaiah Chowdary Nannapaneni
  • Publication number: 20130060031
    Abstract: The present invention relates to an improved and novel process for the preparation of highly pure (>99.8%) (+)-2(S)-(4,6-dimethylpyrimidin-2-yloxy)-3-methoxy-3,3-diphenylpropionic acid (Ambrisentan) of formula (I).
    Type: Application
    Filed: March 15, 2010
    Publication date: March 7, 2013
    Applicant: Natco Pharma Limited
    Inventors: Amala Kompella, Kali Satya Bhujanga Ra Adibhatla, Veera Swamy Balina, Srinivasu Kasa, Venkaiah Chowdary Nannapaneni
  • Publication number: 20070232633
    Abstract: The present invention relates to novel intermediates useful for the preparation of novel phenylaminopyrimidine derivatives, novel phenylaminopyrimidine derivatives. Pharmaceutical composition containing the novel phenylaminopyrimidine derivatives and processes for their preparation. The invention particularly relates to novel Phenyl pyrimidine amine derivatives of the general formula (I). The novel compounds of the formula 1 can be used in the therapy of Chronic Myeloid Leukemia (CML). Since the IC50; 191 values of these molecules are in the range 0.1 to 10.0 nm, these novel compounds are potentially useful for the treatment of CML.
    Type: Application
    Filed: March 5, 2007
    Publication date: October 4, 2007
    Applicant: Natco Pharma Limited
    Inventors: Amala Kompella, Bhujanga Adibhatla Kali Satya, Sreenivas Rachakonda, Khadgapathi Podili, Nannapaneni Venkaiah Chowdary